Quantum Pharma Plc, the growing service-led niche pharmaceutical manufacturer, developer and supplier to the health and care sectors, is pleased to announce a further three out-licensing deals in Germany, though Lamda (UK) Limited, Lamda Laboratories SA and Lamda Pharmaceuticals SA (collectively ‘Lamda’), part of its Niche Pharmaceutical division. These agreements form part of the core strategy for this division.
Under the three licensing, royalty and supply agreements, Lamda will out-license two generic plus and one generic dossiers which Lamda developed. The total fixed licensing fee from these three agreements will be, in aggregate, €375,000 of which €280,000 is payable prior to 31 January 2016. The balance will be payable during late 2016 or early 2017.
Once the products receive a marketing authorisation in Germany Lamda will procure the supply of the manufactured product to the pharmaceutical company for an initial period of five years. This supply agreement is expected to contribute positive margin to the Group from late 2016.
Furthermore, Lamda anticipates that that the launch of these products in Germany, in particular the generic-plus product, will attract interest in other EU markets, leading to increased revenues for the Group.
Andrew Scaife, CEO of Quantum Pharma, said: “As well as providing a number of products in the Niche Pharmaceutical pipeline and in house development for our pipeline Lamda continues to build strategic partnerships with pharmaceutical companies in Europe through its sustained commercialisation of the latent value in its 100+ completed development projects and also through new product development agreements for third parties. Through these deals and the associated supply agreements, Lamda continues to build a sustainable and profitable revenue stream which we expect will continue to grow over the coming years.
“The Niche Pharmaceutical division continues to make good progress as the front end of our product pipeline comes to market and we continue to grow our pipeline and execute further out-licensing agreements into new geographical markets.”
